Diseases, Conditions, Syndromes

Researchers propose studying COVID-19's envelope protein

Understanding any similarities between SARS and COVID-19 inflammation could help in a clinical setting. A protein in the viruses causing COVID-19 and SARS is almost identical. Researchers propose investigating whether FDA-approved ...

Neuroscience

Building corticocerebellar neural circuits

In a comprehensive study, researchers from the Rijli group found that a single Hox transcription factor expressed in a group of neurons of the pontine nucleus—the cerebral cortex most important brainstem relay to the cerebellum—determines ...

Medications

Repurposing approved drugs for COVID-19 at an accelerated pace

The United States' Defense Advanced Research Projects Agency (DARPA) has signed an Agreement worth up to $16 million over the next year with the Wyss Institute for Biologically Inspired Engineering at Harvard University to ...

Oncology & Cancer

Outcomes equal for AYA Hodgkin therapy at peds, adult centers

(HealthDay)—For adolescent and young adult (AYA) patients with Hodgkin lymphoma (HL), treatment strategies differ, but outcomes are equivalent with treatment at pediatric and adult centers, according to a study published ...

Diseases, Conditions, Syndromes

Using a smartphone to diagnose COVID-19 at home

In Pennsylvania and other U.S. states, one of the keys to safely reopening society amid the COVID-19 pandemic is providing sufficient testing so that new cases of the disease do not overwhelm the public healthcare system. ...

Diseases, Conditions, Syndromes

Contact tracing apps: Which countries are doing what

Several countries fighting the coronavirus outbreak are using—or debating—phone apps that trace a person's movements and who they come into contact with, allowing authorities to keep track of infections and alert people ...

Oncology & Cancer

FDA approves first ever treatment for neurofibromatosis

The U.S. Food and Drug Administration (FDA) has approved Koselugo (selumetinib) for use in patients with inoperable plexiform neurofibromas, a common manifestation in the disease neurofibromatosis type one (NF1). The FDA's ...

page 1 from 5